SINTX Technologies, Inc. (SINT) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. SINTX Technologies is an advanced ceramics company specializing in silicon nitride (Si3N4) for medical, industrial, and agribiotech applications. The company operates as a single segment, focusing on biomedical solutions (spinal, foot & ankle implants) and industrial components. In October 2025, the company received FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, with initial commercial sales recognized in the first half of 2026.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (in thousands) |
|---|---|
| Total Revenue | $832 |
| Net Loss | $(5,527) |
| Net Loss Attributable to Common Stockholders | $(6,453) |
| Gross Profit | $422 |
| Operating Loss | $(6,095) |
| Cash and Cash Equivalents (Ending) | $3,590 |
| Net Cash Used in Operating Activities | $(5,258) |
| Accumulated Deficit | $(297,629) |
| Debt (Current) | $102 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 60% to $832,000 from $520,000 in the prior year period. Product revenue rose 91% to $747,000, driven by OEM technical manufacturing sales and initial sales of the SiNAPTIC system. Grant and contract revenue declined 34% to $85,000.
- Expense Reallocation: Research and Development (R&D) expenses decreased 60% to $937,000, while General and Administrative (G&A) expenses increased 78% to $4.85 million. This shift reflects a strategic reallocation of overhead costs from R&D to G&A as the company transitions toward commercialization.
- Deemed Dividend: A non-cash deemed dividend of $926,000 was recorded due to a warrant modification in June 2026, increasing the net loss attributable to common stockholders.
- Inventory Build-up: Inventories increased significantly from $1,044,000 to $2,252,000, resulting in a $1.2 million cash outflow in operating activities.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has concluded that substantial doubt remains regarding the company's ability to continue as a going concern for at least 12 months from the filing date. Continued operations depend on increasing sales, achieving profitability, and securing additional financing.
- Capital Resources: The company raised approximately $4.5 million in a private placement in June 2026. It also has an "At-The-Market" (ATM) offering program with $5.1 million of capacity remaining (out of $6.4 million total).
- Strategic Focus: Management is concentrating resources on high-growth healthcare sectors while maintaining industrial operations as a revenue foundation. Cost-saving measures include a sublease of the SINTX Armor facility, expected to save approximately $1.0 million over the term.
- Risks: Key risks include the inability to secure additional funding, failure to achieve commercial adoption of new medical products, and continued operating losses.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $3.59 million cash balance against the $5.3 million operating cash burn rate for the first half of 2026.
- Revenue Sustainability: Assess the durability of the 91% product revenue growth, specifically the contribution from the newly cleared SiNAPTIC system versus one-time OEM orders.
- Warrant Liability: Monitor the fair value of derivative liabilities (warrants), which decreased by $482,000 in the period, impacting non-cash income.
- Inventory Levels: Investigate the rationale behind the 116% increase in inventory levels and the associated cash drag.
- Financing Terms: Review the terms of the June 2026 private placement, specifically the "call" provisions on Class B warrants triggered by revenue milestones.